Literature DB >> 19892699

Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter.

Jacob Andersen1, Lars Olsen, Kasper B Hansen, Olivier Taboureau, Flemming S Jørgensen, Anne Marie Jørgensen, Benny Bang-Andersen, Jan Egebjerg, Kristian Strømgaard, Anders S Kristensen.   

Abstract

The serotonin transporter (SERT) regulates extracellular levels of the neurotransmitter serotonin (5-hydroxytryptamine) in the brain by facilitating uptake of released 5-hydroxytryptamine into neuronal cells. SERT is the target for widely used antidepressant drugs, including imipramine, fluoxetine, and (S)-citalopram, which are competitive inhibitors of the transport function. Knowledge of the molecular details of the antidepressant binding sites in SERT has been limited due to lack of structural data on SERT. Here, we present a characterization of the (S)-citalopram binding pocket in human SERT (hSERT) using mutational and computational approaches. Comparative modeling and ligand docking reveal that (S)-citalopram fits into the hSERT substrate binding pocket, where (S)-citalopram can adopt a number of different binding orientations. We find, however, that only one of these binding modes is functionally relevant from studying the effects of 64 point mutations around the putative substrate binding site. The mutational mapping also identify novel hSERT residues that are crucial for (S)-citalopram binding. The model defines the molecular determinants for (S)-citalopram binding to hSERT and demonstrates that the antidepressant binding site overlaps with the substrate binding site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892699      PMCID: PMC2804362          DOI: 10.1074/jbc.M109.072587

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Neurotransmitter transporters in the central nervous system.

Authors:  J Masson; C Sagné; M Hamon; S El Mestikawy
Journal:  Pharmacol Rev       Date:  1999-09       Impact factor: 25.468

2.  Generation of a 3D model for human GABA transporter hGAT-1 using molecular modeling and investigation of the binding of GABA.

Authors:  Thomas Wein; Klaus T Wanner
Journal:  J Mol Model       Date:  2009-06-09       Impact factor: 1.810

3.  Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation.

Authors:  F Lin; H A Lester; S Mager
Journal:  Biophys J       Date:  1996-12       Impact factor: 4.033

4.  Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter.

Authors:  E L Barker; K R Moore; F Rakhshan; R D Blakely
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

5.  The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.

Authors:  J Hyttel; K P Bøgesø; J Perregaard; C Sánchez
Journal:  J Neural Transm Gen Sect       Date:  1992

6.  A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.

Authors:  D Graham; H Esnaud; E Habert; S Z Langer
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

7.  The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding.

Authors:  J G Chen; A Sachpatzidis; G Rudnick
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

8.  Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes.

Authors:  Sotiria Tavoulari; Lucy R Forrest; Gary Rudnick
Journal:  J Neurosci       Date:  2009-07-29       Impact factor: 6.167

9.  Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures.

Authors:  Zheng Zhou; Juan Zhen; Nathan K Karpowich; Christopher J Law; Maarten E A Reith; Da-Neng Wang
Journal:  Nat Struct Mol Biol       Date:  2009-05-10       Impact factor: 15.369

10.  High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol.

Authors:  E L Barker; M A Perlman; E M Adkins; W J Houlihan; Z B Pristupa; H B Niznik; R D Blakely
Journal:  J Biol Chem       Date:  1998-07-31       Impact factor: 5.157

View more
  48 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

Review 2.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

3.  Importance of the Extracellular Loop 4 in the Human Serotonin Transporter for Inhibitor Binding and Substrate Translocation.

Authors:  Hafsteinn Rannversson; Pamela Wilson; Kristina Birch Kristensen; Steffen Sinning; Anders Skov Kristensen; Kristian Strømgaard; Jacob Andersen
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

4.  Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues.

Authors:  F Sakloth; R Kolanos; P D Mosier; J S Bonano; M L Banks; J S Partilla; M H Baumann; S S Negus; R A Glennon
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

5.  Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.

Authors:  Peng Zhang; George Cyriac; Theresa Kopajtic; Yongfang Zhao; Jonathan A Javitch; Jonathan L Katz; Amy Hauck Newman
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

6.  Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters.

Authors:  Jacob Andersen; Nicolai Stuhr-Hansen; Linda Zachariassen; Søren Toubro; Stinna M R Hansen; Jonas N N Eildal; Andrew D Bond; Klaus P Bøgesø; Benny Bang-Andersen; Anders S Kristensen; Kristian Strømgaard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

Review 7.  Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.

Authors:  Sankar Manepalli; Christopher K Surratt; Jeffry D Madura; Tammy L Nolan
Journal:  AAPS J       Date:  2012-08-24       Impact factor: 4.009

8.  Effects of mutations in Aedes aegypti sterol carrier protein-2 on the biological function of the protein.

Authors:  James T Radek; David H Dyer; Que Lan
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

9.  Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.

Authors:  Ashwini K Banala; Peng Zhang; Per Plenge; George Cyriac; Theresa Kopajtic; Jonathan L Katz; Claus Juul Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2013-12-02       Impact factor: 7.446

10.  Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter.

Authors:  Per Plenge; Lei Shi; Thijs Beuming; Jerez Te; Amy Hauck Newman; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.